Table 3.
Estimation of potential outcome means between second − line drugs: Treatment effect model with inverse probability weighting and regression adjustment
| Treatment | POM | Lower limit | Upper limit |
|---|---|---|---|
| ITT | |||
| SGLT2i | 0.037 | 0.012 | 0.063 |
| DPP4i | 0.133 | 0.122 | 0.143 |
| TZD | 0.175 | 0.157 | 0.193 |
| SU | 0.179 | 0.173 | 0.185 |
| PPA | |||
| SGLT2i | 0.024 | 0.002 | 0.046 |
| DPP4i | 0.146 | 0.132 | 0.161 |
| TZD | 0.194 | 0.172 | 0.216 |
| SU | 0.201 | 0.193 | 0.208 |
| Modified ITT | |||
| SGLT2i | 0.037 | 0.012 | 0.063 |
| DPP4i | 0.133 | 0.122 | 0.143 |
| TZD | 0.175 | 0.157 | 0.193 |
| SU | 0.179 | 0.173 | 0.185 |
DPP4i: Dipeptidyl peptidase-4 inhibitors; ITT: Intention-to-reat; POM: Potential outcome mean; PPA: Per-protocol analysis; SGLT2i: Sodium-glucose cotransporter-2 inhibitors; SU: Sulfonylureas; TZD: Thiazolidinediones